A $16 million research initiative is bringing together scientists from six U.S. cancer centers to build on recent breakthroughs in…
Articles by Michela Luciano, PhD
Weekly treatment with Context Therapeutics’ CTIM-76 was generally well tolerated and shrank tumors in some people with heavily pretreated…
Preliminary Phase 1 trial data show that uTREAT, Curasight’s experimental targeted cancer therapy, was safely delivered to aggressive solid…
The first patient has been dosed in a Phase 2 trial testing an all-oral, triple-combination treatment that includes Cellcentric’s…
Merck is set to acquire Terns Pharmaceuticals in a $6.7 billion deal aimed at expanding its oncology pipeline, including…
Myosin Therapeutics has been awarded $2 million in funding to support a Phase 1/2 clinical trial testing its lead…
Overt Bio said it established a clinical advisory board to support the development of OVT-101, its lead investigational CAR…
A long-lasting gel used to help protect the bowel during radiation therapy for prostate cancer may be successfully used in…
Olverembatinib (HQP1351), used in combination with low-intensity chemotherapy, has shown encouraging therapeutic potential — along with a favorable safety profile…
Komzifti (ziftomenib), a once-daily oral therapy approved for certain people with acute myeloid leukemia (AML), is now included in the…